438 related articles for article (PubMed ID: 19269737)
1. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
2. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
3. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2007 Sep; 255(1):12-25. PubMed ID: 17383090
[TBL] [Abstract][Full Text] [Related]
5. Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kumar C; Purandare AV; Lee FY; Lorenzi MV
Oncogene; 2009 Jun; 28(24):2305-13. PubMed ID: 19421140
[TBL] [Abstract][Full Text] [Related]
6. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
7. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
8. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
[TBL] [Abstract][Full Text] [Related]
9. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
10. The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms.
Smith CA; Fan G
Hum Pathol; 2008 Jun; 39(6):795-810. PubMed ID: 18538168
[TBL] [Abstract][Full Text] [Related]
11. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.
Levine RL; Pardanani A; Tefferi A; Gilliland DG
Nat Rev Cancer; 2007 Sep; 7(9):673-83. PubMed ID: 17721432
[TBL] [Abstract][Full Text] [Related]
12. JAK2 and MPL mutations in myeloproliferative neoplasms.
Koppikar P; Levine RL
Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
[TBL] [Abstract][Full Text] [Related]
14. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
15. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
17. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
18. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Agarwal MB
J Assoc Physicians India; 2007 Jul; 55():507-10. PubMed ID: 17907502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]